Dr Dan Thurley
Medical Affairs Working internationally for renowned pharmaceutical companies, Roche and Merck Serono, Dan has led local, regional, and global teams for 20+ years in general management (NZ and HK) and medical affairs (ANZ, UK, Europe, and APAC). During this time, Dan delivered market-leading product launches, successful pre-launch and launch readiness activities, and product registrations across EU and Australia. Dan has designed, led, and published international clinical trials both in hospitals (Phase I-III) and as sponsor (Phase IV). Dan has been a Board Director for several Chambers of Commerce (HK), and President (HK) and Director (NZ) of national Pharmaceutical company Associations. Dan is a Consultant in Pharmaceutical Medicine, and previously worked in Medical Oncology at Royal North Shore Hospital (Sydney). For a decade, Dan was an Examiner and Diploma convener for the Pharmaceutical Medicine Faculty of the UK Royal College of Physicians. Currently, Dan is an Associate Professor in the Faculty of Medicine and Health at the University of Sydney and is known for having an adaptive and holistic view of healthcare with the patient at the center. He is committed to changing the landscape of health equity through novel approaches to complex challenges. Most recently, Dan has been working with an Industry-leading team for the creation of a Medical Affairs Competency Framework. Kieran Schneemann
Government Affairs & Policy For over 30 years, Kieran has been heavily involved in the advancement of the ANZ healthcare industry via his roles in the government and private sectors. He has earned a distinguished reputation for his contribution towards the building of strong collaborations and trust between local and federal government, healthcare associations, media, and pharmaceutical organizations. With a background in government as Chief of Staff, as CEO of the Pharmacy Guild and of Medicines Australia, and leading the government and corporate affairs department for a multinational pharmaceutical company, AstraZeneca, Kieran intimately understands the nuances and intricacies of accessing medicines in Australia. With a career dedicated to improving the quality and equitability of healthcare for all through his board (ACTA, CanTeen Australia) and executive leadership positions, Kieran has proven his commitment to Australian and New Zealand patients. Kate Webb
Market Access For 20+ years, Kate has developed strategies for reimbursement, health economics, and market access locally, regionally, and globally. Working for internationally renowned pharmaceutical companies including Takeda, Pfizer, Sanofi, and AstraZeneca, and a leading consultancy Covance, Kate has led and delivered pricing & reimbursement applications and defenses, health technology assessments, and projects in health economics and outcomes research. These have spanned new-to-market technologies & in-market and LOE products, including life-cycle management of additional indications for new technologies & market optimization for mature products. Kate has served on several Medicine Australia’s technical committees and contributed to a number of reviews of HTA and access to cancer medicines in Australia. With a global perspective, a reputation for excellence, and a passionate commitment to delivering results, Kate continues to change the lives of patients globally. |
Marty Hayes
Sales & Marketing For 20+ years, Martin has worked within the Australian healthcare sector supporting pharmaceutical and medical device organizations to achieve their maximum commercial potential. Working with highly reputable multinational companies including Roche, Eli Lilly, Siemens, and Johnson & Johnson, Martin has built and led high-performing sales teams and executed sales strategies to significantly grow market share and revenue of products across the full lifecycle from new innovative best-in-class to mature and LOE assets. Through contract negotiations, third-party contract sales team management, sales force effectiveness, new product planning, launch excellence, international capabilities leadership, and strategic key account management, Martin has developed simplified sales solutions for the complex Australian healthcare market. Nicholette Conway
Commercial Development With over 25 years of experience, Nicholette has worked in pharmaceuticals, medical devices, and diagnostics, focusing on patient access to innovative treatments. She has collaborated with precision medicine and health tech startups, biotech and medtech scale-ups, and worked in major pharmaceutical companies including Eli Lilly, Amgen, MSD, and Bayer. Nicholette's expertise spans clinical trial development (Phase 1-4), new product planning (NPP), market access, patient advocacy, and reimbursement (MSAC & PBAC). She has successfully led product development in oncology, rare diseases, infectious diseases, reproductive technologies, and genetics, through a pragmatic and holistic approach and extensive stakeholder engagement, especially with patient support and advocacy groups. Nicholette is an experienced board member and chair (Genetic Alliance Australia) and is deeply involved in the progress of the Australian healthcare sector by leading multiple commercialization, education, and workforce development initiatives. Vanessa Meikle
People & Culture For 20+ years, Vanessa has partnered with start-up, scale-up, and established healthcare and life sciences organizations to attract, hire, and develop emerging and seasoned talent across the full breadth of the R&D and commercialization value chain in local, regional, and global positions. With a focus on people and culture, Vanessa has helped design and develop talent acquisition, talent management, and talent development frameworks that have supported pharmaceutical, medical device, health technology, biotech, and medtech companies through their transformations and growth, thereby giving them the platform to accelerate and achieve sustainable success. A board director and a member of AusBiotech, BioNSW, and BioMelbourne Network, Vanessa is committed to the progress of the ANZ and global healthcare ecosystem. James Jones
Operations & Governance For 25+ years, James has led and delivered commercial results across ANZ, US, and global markets in Rare Diseases, Specialty Care, Oncology, Primary Care, and OTC therapy areas for internationally recognized pharmaceutical companies including Takeda, Nycomed, AstraZeneca, Sanofi, and Schering Plough. Building and leading high-performing teams and organizations James has delivered results with multiple assets across the full lifecycle from pipeline, launch to loss of exclusivity, interacting and negotiating for registration and reimbursement, and ultimately to commercial success. An experienced board director (Medicines Australia and Consumer Healthcare Products Australia) deeply involved in the development of the Australian healthcare industry and an experienced consultant assessing and evaluating assets for global organizations, Venture Capital, and Private Equity companies looking to enter Australia and New Zealand. |
For further information please contact Axis Health Co at [email protected]